Making Tomorrow’s
Cancer Treatment Better

We are Isofol

Isofol is a publicly listed biotechnology company in clinical phase that is developing the drug candidate arfolitixorin that aims to increase the efficacy of standard treatments for patients with severe forms of cancer.

Our goal is s to have a central impact on tomorrow’s cancer care – helping more patients respond better to their treatment, improve their prognosis, and gain more time with life.

Isofol’s shares are traded on Nasdaq Stockholm.

The subscription price for warrants of series TO2 in Isofol has been set at SEK 0.95 and the exercise period commences on 16 November 2026

Regulatory

Isofol Medical AB (publ) publishes interim report, January–September 2026

Regulatory

Isofol provides a new update on the ongoing phase Ib/II clinical study of arfolitixorin

Regulatory

2026-11-18

Investor & Scientific Update

Isofol invited investors, shareholders, and other stakeholders to an Investor & Scientific Update in Stockholm on November 12. The principal investigator of the company’s ongoing clinical study, Professor Sebastian Stintzing of Charité – Universitätsmedizin Berlin, discussed developments in colorectal cancer, current and future treatment options, and the latest results from the ongoing study of arfolitixorin. Professor Frits Peters at the Laboratory Medical Oncology, Amsterdam UMC and the Department of Biochemistry, Medical University of Gdansk, provided the pharmacological background regarding the study’s optimized dosing regimen and explain why it is expected to further enhance the efficacy of arfolitixorin.

2026-11-12

Preliminary results from phase Ib/II study

Isofol’s Chief Medical Officer Roger Tell discusses the preliminary results from the ongoing phase Ib/II study.

CMO, Roger Tell

2026-11-04

Biostock Life Science Summit 2026

Isofol participated in Biostock Life Science Summit 2026 during November. CEO, Petter Segelman Lindqvist, provided an update on the company and the ongoing clinical phase Ib/II study.


For investors

Scroll to Top